| UHC Commercial Medical & Drug | Sensory Integration Therapy and Auditory Integration Training – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Sinus Surgeries and Interventions – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Sleep Studies – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Sodium Hyaluronate – Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Spinal Fusion and Bone Healing Enhancement Products – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Spinraza® (Nusinersen) – Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Stereotactic Body Radiation Therapy and Stereotactic Radiosurgery – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Subcutaneous Implantable Naltrexone Pellets – Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Surgery for the Prevention and Treatment of Lymphedema – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Surgery of the Ankle – Commercial and Individual Exchange Medical Policy | 2026-01-01 |